Lan Feifei, Xu Jian, Zhong Qiuyuan, Cen Chunjing, Wei Chunmiao
Department of Ultrasound, Guangxi International Zhuang Medical Hospital Nanning 530200, Guangxi, China.
Department of Electrocardiogram Diagnosis, Guangxi International Zhuang Medical Hospital Nanning 530200, Guangxi, China.
Am J Transl Res. 2024 Jul 15;16(7):2953-2962. doi: 10.62347/NHTG3720. eCollection 2024.
Objectives To assess the benefits of Zhuang medicine in treating rheumatoid arthritis (RA), with a focus on cardiac tricuspid annulus displacement and heart rate variability (HRV), thereby providing evidence supporting Zhuang medicine theories.
This retrospective study analyzed echocardiographic data and HRV of 30 healthy subjects and 60 RA patients. RA patients were divided into two groups for a 6-month treatment: 30 received iguratimod (control group), and 30 underwent combined Zhuang medicine and needle-pricking therapy (test group). Echocardiographic assessments and HRV measures were recorded both before and after treatment.
Compared to the healthy group, RA patients showed increased late diastolic tricuspid annular velocity. However, early diastolic tricuspid annular velocity to late diastolic tricuspid annular velocity ratios, tricuspid annular plane systolic excursion (TAPSE), and the standard deviation of average normal RR intervals (SDANN) were significantly lower (all P<0.05). After treatment, the test group exhibited higher clinical efficacy (90% vs. 56.67% in the control group). Significant improvements were observed in TAPSE and HRV indices [SDANN, standard deviation of the RR intervals (SDNN), root mean square of successive RR interval differences (RMSSD), and the percentage of adjacent RR interval differences greater than 50 milliseconds (PNN50)] in the test group (all P<0.05). Additionally, a positive correlation was noted among these measurments.
Zhuang medicine significantly enhances right ventricular function and autonomic balance in RA patients, thus affirming its therapeutic potential.
目的 评估壮医治疗类风湿关节炎(RA)的疗效,重点关注心脏三尖瓣环位移和心率变异性(HRV),从而为壮医理论提供支持证据。
本回顾性研究分析了30名健康受试者和60名RA患者的超声心动图数据及HRV。RA患者分为两组进行为期6个月的治疗:30例接受艾拉莫德治疗(对照组),30例接受壮医联合针刺治疗(试验组)。记录治疗前后的超声心动图评估和HRV测量结果。
与健康组相比,RA患者舒张晚期三尖瓣环速度增加。然而,舒张早期三尖瓣环速度与舒张晚期三尖瓣环速度之比、三尖瓣环平面收缩期位移(TAPSE)以及平均正常RR间期标准差(SDANN)显著降低(均P<0.05)。治疗后,试验组临床疗效更高(90% vs. 对照组的56.67%)。试验组的TAPSE和HRV指标[SDANN、RR间期标准差(SDNN)、连续RR间期差值的均方根(RMSSD)以及相邻RR间期差值大于50毫秒的百分比(PNN50)]有显著改善(均P<0.05)。此外,这些测量值之间存在正相关。
壮医可显著增强RA患者的右心室功能和自主神经平衡,从而肯定了其治疗潜力。